Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

Simon Fraser University

$25,000.00

Low-shear, scalable microfluidic sorting of platelets and leukocytes for pooled platelet lysate

FY 2017-18

Summary
Extem supplies research grade mesenchymal stem cells (MSCs) to the health research community and islooking to differentiate themselves by providing a proprietary human derived growth media. MSCs have manyapplications that are important to the future health of Canadians, such as: applications in tissue engineering andregenerative medicine; drug screening using human tissues prior to clinical trials; and treatment of disease bymodulating (enhancing or suppressing) the immune system. MSCs are typically grown in fetal bovine serum(FBS), derived from cows. However, in order to avoid xenotropic complications, the stem cell industry ismoving away from products that are derived from non-human species. Other disadvantages of FBS include:batch to batch variability; unexpected cell growth characteristics; and contamination issues. A betterstandardized human derived solution would solve many of these problems. Pooled Platelet Lysate (PPL) hasbeen identified as a viable alternative to FBS. PPL is produced by means of double centrifugation (DC) ofwhole blood. However, existing methods of producing PPL lack rigorous quality control, standardization, andcan activate cells. For example, DC-based PPL can result in an up to 50% loss in cell viability due to activationof cells under fluid shear stress. Extem needs to develop a more economical solution that integrates beneficialquality control and standardization procedures. Extem and microinstrumentation expert Dr. Gray at SimonFraser University (SFU) propose a low shear, high throughput scalable microfluidic whole blood sorter withthe goal of optimizing designs to result in as many viable platelets as possible over a given time period (highthroughput). Individual chips will be optimized both individually and for use in arrays to increase throughput.Chips will be designed with the goal of eventual mass production, with manufacturing constraints consideredin all phases of device design. The development of such a technology will allow Extem and Canadian healthresearchers to remain leaders in the production and application of stem cells by providing MSCs grown in acost-effective human-derived media.
Program
Engage Grants Program
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
514537-2017
Name nom
Gray, Bonnie
Department département
Engineering Science, School of
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Low-shear, scalable microfluidic sorting of platelets and leukocytes for pooled platelet lysate
Keyword
NSERC
Application summary
Extem supplies research grade mesenchymal stem cells (MSCs) to the health research community and islooking to differentiate themselves by providing a proprietary human derived growth media. MSCs have manyapplications that are important to the future health of Canadians, such as: applications in tissue engineering andregenerative medicine; drug screening using human tissues prior to clinical trials; and treatment of disease bymodulating (enhancing or suppressing) the immune system. MSCs are typically grown in fetal bovine serum(FBS), derived from cows. However, in order to avoid xenotropic complications, the stem cell industry ismoving away from products that are derived from non-human species. Other disadvantages of FBS include:batch to batch variability; unexpected cell growth characteristics; and contamination issues. A betterstandardized human derived solution would solve many of these problems. Pooled Platelet Lysate (PPL) hasbeen identified as a viable alternative to FBS. PPL is produced by means of double centrifugation (DC) ofwhole blood. However, existing methods of producing PPL lack rigorous quality control, standardization, andcan activate cells. For example, DC-based PPL can result in an up to 50% loss in cell viability due to activationof cells under fluid shear stress. Extem needs to develop a more economical solution that integrates beneficialquality control and standardization procedures. Extem and microinstrumentation expert Dr. Gray at SimonFraser University (SFU) propose a low shear, high throughput scalable microfluidic whole blood sorter withthe goal of optimizing designs to result in as many viable platelets as possible over a given time period (highthroughput). Individual chips will be optimized both individually and for use in arrays to increase throughput.Chips will be designed with the goal of eventual mass production, with manufacturing constraints consideredin all phases of device design. The development of such a technology will allow Extem and Canadian healthresearchers to remain leaders in the production and application of stem cells by providing MSCs grown in acost-effective human-derived media.